Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ITGAV | P06756 | 4/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.34 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990238 | 0.90 | NNMT (0.49) | NNMTGRM5ASIC3ALDH1A1ALOX5AP | |
| SCHEMBL16196626 | 0.84 | CYP11B2 (0.50) | NNMTASIC3ALOX5APFEN1PARP10 | |
| SCHEMBL25950314 | 0.83 | NNMT (0.51) | NNMTGRM5ASIC3ALOX5APFEN1 | |
| SCHEMBL29809722 | 0.74 | NNMT (0.59) | NNMTGRM5ASIC3ALOX5APFEN1 | |
| SCHEMBL20731178 | 0.74 | NNMT (0.59) | NNMTGRM5ASIC3ALOX5APFEN1 | |
| SCHEMBL30507029 | 0.74 | NNMT (0.55) | NNMTGRM5ASIC3ALOX5APFEN1 | |
| SCHEMBL15951410 | 0.74 | NNMT (0.59) | NNMTGRM5ASIC3ALDH1A1ALOX5AP | |
| SCHEMBL1258438 | 0.74 | NNMT (0.55) | NNMTGRM5ASIC3ALOX5APFEN1 | |
| SCHEMBL31000386 | 0.74 | NNMT (0.55) | NNMTGRM5ASIC3ALDH1A1ALOX5AP | |
| SCHEMBL1258214 | 0.74 | NNMT (0.55) | NNMTGRM5ASIC3ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361765-B2 | Process for the preparation of CCR-2 antagonists | MERCK & CO., INC. (US) | 2008-04-22 | — | — | US | claimed |
| US-20070135475-A1 | Process for the preparation of ccr-2 antagonists | MERCK SHARP & DOHME CORP. | 2007-06-14 | — | — | US | claimed |
| JP-2007509944-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682500-A1 | PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST | Merck & Co., Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005044795-A1 | PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135475-A1 | Process for the preparation of ccr-2 antagonists | CCR1, CCR2, CCR4 | NNMT 1937/4885GRM5 357/4885ASIC3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.